about
Translational control in the stress adaptive response of cancer cells: a novel role for the heat shock protein TRAP1Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?Pondering the puzzle of PML (promyelocytic leukemia) nuclear bodies: can we fit the pieces together using an RNA regulon?Initiation factor eIF2-independent mode of c-Src mRNA translation occurs via an internal ribosome entry site.Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.When will resistance be futile?eIF4E and eIF4GI have distinct and differential imprints on multiple myeloma's proteome and signaling.Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.The eIF4E RNA regulon promotes the Akt signaling pathway.The oncogene eIF4E: using biochemical insights to target cancer.Importin 8 mediates m7G cap-sensitive nuclear import of the eukaryotic translation initiation factor eIF4E.Translational control gone awry: a new mechanism of tumorigenesis and novel targets of cancer treatments.Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.The biological and therapeutic relevance of mRNA translation in cancer.Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.Cap-dependent translation initiation factor eIF4E: an emerging anticancer drug target.Aiding and abetting cancer: mRNA export and the nuclear pore.Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond.The eukaryotic translation initiation factor eIF4E in the nucleus: taking the road less traveled.Targeting translation: eIF4E as an emerging anticancer drug target.Targeting of protein translation as a new treatment paradigm for prostate cancer.The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation.The eukaryotic translation initiation factor eIF4E wears a "cap" for many occasions.Anti-tumor effect of ribavirin in combination with interferon-α on renal cell carcinoma cell lines in vitro.Ribavirin targets eIF4E dependent Akt survival signaling.Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-κB and is aberrantly regulated in acute myeloid leukemia.Conformational changes induced in the eukaryotic translation initiation factor eIF4E by a clinically relevant inhibitor, ribavirin triphosphate.The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy.A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML).Inhibition of eIF4E cooperates with chemotherapy and immunotherapy in renal cell carcinoma.Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation.Ribavirin as a potential therapeutic for atypical teratoid/rhabdoid tumors.The Impact of Post-transcriptional Control: Better Living Through RNA Regulons
P2860
Q24338136-B4A7800B-DCDC-4053-8BFB-ADC08C114EE2Q24594939-17A2C5D0-9D97-4AFB-A4A3-33FFAC319E6AQ28755220-9BB59676-7702-41F1-A59B-A5D2FBDF29D4Q33648488-FEBFBFBE-75F7-4517-A1D9-CB85240C8AFCQ34173253-BBB06F9F-700F-4E65-A3AD-1C767EBE4208Q34715457-176DF398-3540-41A3-B615-669842CF580BQ35552009-7371E2E2-B35C-4E52-B2FC-4B6037675E73Q35758763-C939E0E6-00F4-476D-909A-8C5C25A85136Q36527188-3B6D3429-068C-44D3-AA51-64F2D7E126E0Q36842143-79AEA0ED-CFAB-484D-8622-76D8B1597807Q36904927-0E534057-4576-44D1-8FBA-20716D56470CQ37801949-18A1D015-0119-43D8-865C-34878DF004C1Q37837732-B06F70A2-D02E-4677-8C1F-A5EE0A66A01DQ37848652-8B1FB8FA-2FFC-4671-BAC6-011440511BEBQ37865381-CC856838-C811-4336-8968-C38C7D66F5B3Q38001940-56355761-CF74-48A9-854F-DA1518B2963EQ38098701-E88AF98F-3996-41F4-9F81-4F81B76F77AFQ38227377-066BC118-CF49-48E6-8048-889FB07C3E1EQ38289051-0B839E01-E6B5-4551-B701-88D1C74B785CQ38699320-EFAC180E-9527-43FA-A2B5-E64233CAA007Q39172901-7F8AB77E-DA00-4F5D-86A8-C3935F96650EQ39295500-6E356B6E-7B53-4047-8959-C3996C76E97AQ39549442-BBF3D4F7-CD05-4A3B-AC72-B1602492528AQ39869989-2AB5F762-1CB1-4D74-AB4C-A162C78056B9Q39950178-304BBB9E-61A0-442F-9EF6-696A75D2F7F0Q40429761-782CEF6A-3515-4BE3-809C-520BB8080628Q40616450-7296A2A9-0B31-4E5E-AC0A-54BC7B999FCFQ40872139-5DC7FBCA-68C6-47DE-90A5-F3DEF44C1E87Q41036251-9EC6063E-1813-475E-9893-01310D833094Q43087319-565B7ED5-81AC-44E4-AB68-4B6A532E3E03Q43089875-C651BD6D-4299-491D-B3CD-7CF11F0BD3FDQ47584869-AB28DCBC-6A84-4BC2-A2BE-B3EFEC1B0744Q47720139-6A19A91A-690A-4DCE-8522-9ACB6FED0E02Q52682258-4DCFB571-7AFE-41FC-8187-4AEF64F68388Q59130174-70C0F95E-85E1-406E-8A1A-B9084B9205FE
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Further evidence that ribavirin interacts with eIF4E
@ast
Further evidence that ribavirin interacts with eIF4E
@en
type
label
Further evidence that ribavirin interacts with eIF4E
@ast
Further evidence that ribavirin interacts with eIF4E
@en
prefLabel
Further evidence that ribavirin interacts with eIF4E
@ast
Further evidence that ribavirin interacts with eIF4E
@en
P2093
P2860
P356
P1433
P1476
Further evidence that ribavirin interacts with eIF4E
@en
P2093
Alex Kentsis
Biljana Culjkovic
Clifford E Soll
Ivan Topisirovic
Katherine L B Borden
Laurent Volpon
P2860
P304
P356
10.1261/RNA.2238705
P407
P577
2005-10-26T00:00:00Z